ClinicalTrials.gg
CompletedNCT02508532Updated Jun 21, 2022Results posted

(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors

A Phase 1 interventional study of Avapritinib in Gastrointestinal Stromal Tumors (GIST) and Other Relapsed or Refractory Solid Tumors, sponsored by Blueprint Medicines Corporation. Completed at 19 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-06-21.

Sponsored by Blueprint Medicines Corporation (part of Sanofi) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Gastrointestinal Stromal Tumors with a site in United States — 19 open to participants now, 29 under way, 5 of them phase 3. Gastrointestinal Stromal Tumors · United States.

Enrollment
18th of 116
250 · median 55
Started
2015
with 4 others
Phase 1
32 of 139
3 open now
Registered
90th of 139
by date
Lead sponsor
3 of 139
Blueprint Medicines Corporation

Among the 139 studies in Gastrointestinal Stromal Tumors with a site in United States, this one is the 18th largest by enrollment of the 116 interventional ones that give a count, is one of 5 that started in 2015, is one of 32 in phase 1, and was the 90th registered.

Gastrointestinal Stromal Tumors

343 studies on the registry are indexed under Gastrointestinal Stromal Tumors; 61 are open to participants now.

Browse Gastrointestinal Stromal Tumors studies →

Open to participants now

19 of the 139 studies in Gastrointestinal Stromal Tumors with a site in United States are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 49 Gastrointestinal Stromal Tumors studies recruiting now, 38 (78%) set no upper age limit and 4 (8%) stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Gastrointestinal Stromal Tumors with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult patients with unresectable GIST or other relapsed or refractory solid tumors. The study consists of 2 parts, a dose-escalation part (Part 1) and an expansion part (Part 2).

03

Conditions studied

  • Gastrointestinal Stromal Tumors (GIST)
  • Other Relapsed or Refractory Solid Tumors

Keywords

  • 2L GIST
  • GIST second line
  • GIST gleevec
  • GIST imatinib
  • Second-line GIST clinical trial
  • BLU-285
  • BLU 285
  • BLUE-285
  • BLUE 285
  • Avapritinib
  • GIST imatinib relapse
  • GIST gleevec relapse
  • GIST KIT
  • GIST relapse
  • GIST refractory
  • GIST imatinib intolerance
  • GIST TKI treatment
  • GIST tyrosine kinase inhibitor treatment
  • GIST TKI
  • GIST tyrosine kinase inhibitor
  • Advanced GIST
  • GIST mutations
  • GIST treatments
  • Blueprint GIST
  • Relapsed GIST clinical trial
  • Refractory GIST clinical trial
  • KIT-mutant GIST
  • cancer gist
  • gastrointestinal stromal tumor
  • gist cancer
  • PDGFRA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For Part 1: - or cytologically-confirmed diagnosis of unresectable GIST or another advanced solid tumor. Patients with unresectable GIST must have disease that has progressed following imatinib and at least 1 of the following: sunitinib, regorafenib, sorafenib, dasatinib, pazopanib or an experimental kinase-inhibitor agent, or disease with a D842 mutation in the PDGFRα gene. Patients with an advanced solid tumor other than GIST must have disease without an available effective therapy.

OR For Part 2:

  • Group 1: Patients must have a confirmed diagnosis of unresectable GIST that has progressed following imatinib and at least 1 of the following: sunitinib, regorafenib, sorafenib, dasatinib, pazopanib, or an experimental kinase-inhibitor agent, and the patient does not have a D842V mutation in PDGFRα.
  • Group 2: Patients must have a confirmed diagnosis of unresectable GIST with a D842V mutation in the PDGFRα gene. The PDGFRα mutation will be identified by local or central assessment, either in an sample or a new tumor biopsy obtained prior to treatment with avapritinib.
  • Group 3: Patients must have a confirmed diagnosis of unresectable GIST that has progressed and/or patients must have experienced intolerance to imatinib and not received additional kinase-inhibitor therapy. Patients must not have a known D842V mutation in PDGFRα.
  • Groups 1, 2 and 3: At least 1 defined by 1.1 for patients with GIST.
  • Groups 1 and 2: A tumor sample (archival tissue or a new tumor biopsy) has been submitted for mutational testing.
  • (ECOG) performance status of 0-2

Exclusion criteria

Exclusion Criteria:

  • corrected using Fridericia's formula (QTcF) >450 milliseconds
  • count \<90,000/mL
  • \<1000/mL
  • \<9 g/dL
  • (AST) or alanine aminotransferase (ALT) >3 x the (ULN) if no hepatic are present; >5 × ULN if hepatic metastases are present
  • Total >1.5 × ULN; >3 × ULN with direct bilirubin, >1.5 × ULN in the presence of Gilbert's Disease
  • Estimated (Cockroft-Gault formula) or measured \<40 mL/min Brain or metastases to the brain
  • History of a seizure disorder or requirement for anti-seizure medication
  • Group 3: Patients known to be KIT wild type.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

iRECIST and mRECIST

Versions of RECIST adapted to particular cases. iRECIST is for immunotherapy, where a tumor can look bigger for a while before it shrinks, so growth has to be confirmed on a later scan. mRECIST usually means the version for liver cancer (hepatocellular carcinoma), which measures only the part of a tumor that still has a blood supply.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
250 participants (actual)

Study arms

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 30 mg QD

    Part 1: Patients received a starting dose of 30 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.

    Drug: Avapritinib

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 60 mg QD

    Part 1: Patients received a starting dose of 60 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.

    Drug: Avapritinib

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 90 mg QD

    Part 1: Patients received a starting dose of 90 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.

    Drug: Avapritinib

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 135 mg QD

    Part 1: Patients received a starting dose of 135 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.

    Drug: Avapritinib

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 200 mg QD

    Part 1: Patients received a starting dose of 200 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation. .

    Drug: Avapritinib

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 300 mg QD

    Part 1: Patients received a starting dose of 300 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis.

    Drug: Avapritinib

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 400 mg QD

    Part 1: Patients received a starting dose of 400 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation. Patients that received at least one dose of avapritinib were included in the Part 2 analysis.

    Drug: Avapritinib

  • Experimental
    Part 1 Avapritinib (formerly BLU-285) 600 mg QD

    Part 1: Patients received a starting dose of 600 mg QD for 28 days and they were assessed for dose limiting toxicities (DLT). If no DTLs were observed the dose escalation continued. Patients received avapritinib in continuous 28 day cycles until discontinuation.

    Drug: Avapritinib

  • Experimental
    Part 1 and Part 2 Avapritinib (formerly BLU-285) 300 mg or 400 mg QD

    Part 1 and Part 2: Patients enrolled in Part 1 and Part 2 at a starting dose of 300 or 400 mg QD were included in the Part1/Part 2 safety and efficacy analysis. Patients received avapritinib in continuous 28 day cycles until discontinuation.

    Drug: Avapritinib

Interventions

  • avapritinib tablets

    Also known as: BLU-285

06

What researchers measure

Primary outcomes

  1. Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib

    Patients with event(s) of dose-limiting toxicity

    Time frame: Cycle 1 (28 days) of treatment

  2. Parts 1 and 2: Number of Patients With Adverse Events (AE) and Serious Adverse Events (SAE)

    The overall safety profile of the drug was assessed by reviewing the number of patients with AEs, SAEs and other events. There was no formal statistical analysis. Safety assessments continued for the duration of treatment.

    Time frame: AEs were collected from the start of study drug until 30 days after the last dose, SAEs were collected from the date of the informed consent signature until 30 days after the last dose of study drug, up to 5 years

  3. Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1

    To evaluate objective response rate (ORR) determined by central radiology assessment per mRECIST, version 1.1 in patients with advanced GIST treated with avapritinib. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR

    Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.

Secondary outcomes

  1. Maximum Plasma Drug Concentration (Cmax)

    Maximum plasma drug concentration (Cmax) following a single dose of avapritinib

    Time frame: Cycle 1 Day 1

  2. Time to Maximum Plasma Drug Concentration (Tmax)

    Cycle 1 Day 1 PK time to maximum plasma drug concentration (Tmax)

    Time frame: Cycle 1 Day 1

  3. Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)

    Plasma drug concentration at 24 hours postdose prior to the next daily dose (C24) following a single dose of avapritinib

    Time frame: Cycle 1 Day 1

  4. Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC 0-24)

    Area under the plasma concentration-time curve from time 0 to 24 hours (AUC 0-24) following a single dose of avapritinib

    Time frame: Cycle 1 Day 1

  5. Apparent Oral Clearance Unadjusted for Bioavailability (CL/F)

    Apparent oral clearance unadjusted for bioavailability (CL/F) following a single dose of avapritinib

    Time frame: Cycle 1 Day 1

  6. Apparent Volume of Distribution, Unadjusted for Bioavailability (Vz/F)

    Apparent volume of distribution, unadjusted for bioavailability (Vz/F) following a single dose of avapritinib

    Time frame: Cycle 1 Day 1

  7. Terminal Elimination Half-life (t1/2)

    Terminal elimination half-life (t1/2) following a single dose of avapritinib

    Time frame: Cycle 1 Day 1

  8. Maximum Plasma Drug Concentration (Cmax) at Steady State

    Maximum plasma drug concentration (Cmax) at steady state following 15 days of QD dosing

    Time frame: Cycle 1 Day 15

  9. Time of Maximal Concentration (Tmax) at Steady State

    Time of maximal concentration (Tmax) at steady state following 15 days of QD dosing

    Time frame: Cycle 1 Day 15

  10. Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at Steady State (C24,ss)

    Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at steady state (C24,ss) following 15 days of QD dosing

    Time frame: Cycle 1 Day 15

  11. Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady Sate (AUC0-τ,ss) (τ=24 h)

    Area under the plasma concentration-time curve over the dosing interval at steady sate (AUC0-τ,ss) (τ=24 h) following 15 days of QD dosing

    Time frame: Cycle 1 Day 15

  12. Progression-free Survival Per mRECIST Version 1.1

    Progression-free survival is defined as the time in months from the start of treatment to the date of first documented progression or death due to any cause. Progression-free survival determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST), version 1.1 in patients with advanced GIST. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.

    Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.

  13. Apparent Oral Clearance at Steady State, Unadjusted for Bioavailability (CLss/F)

    Apparent oral clearance at steady state, unadjusted for bioavailability (CLss/F) following 15 days of QD dosing

    Time frame: Cycle 1 Day 15

  14. Clinical Benefit Rate Determined by Central Radiology Assessment Per mRECIST, Version 1.1

    Percent of patients with a complete response, partial response or stable disease lasting more than 16 weeks. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Stable disease is defined as a tumor that does not meet the criteria for progression or for response. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.

    Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.

  15. Response Rate Determined by Central Radiology Assessment Per Choi Criteria

    A complete response is defined as complete disappearance of all target lesions. A partial response is ≥10% decrease tumor size at computed tomography (CT) or ≥15% decrease in tumor attenuation at computed tomography (CT) and no new lesions. The response rate is defined as complete response plus partial response.

    Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.

  16. Duration of Response Determined by Central Radiology Assessment Per mRECIST, Version 1.1

    Duration from time to first documented CR/PR to date of first documented disease progression or death. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR

    Time frame: Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.

  17. Median PFS on Last Prior Anti-cancer Therapy

    Progression Free Survival (PFS) is defined as the time in months from the start of treatment to the date of first documented disease progression or death due to any cause, which ever occurs first. PFS on last prior anti-cancer therapy is defined as the time in months from the start of last prior anti-cancer therapy to progression on that therapy.

    Time frame: Historical data collected at enrollment, all available data on prior therapy was collected

  18. Change From Baseline in Levels of KIT and PDGFRα Mutant Allele Fractions in Peripheral Blood

    Change of mutant allele fraction (MAF) summarizes the largest fold change. Change from baseline only displayed for patients with pre and post treatment MAF measurements. A positive number represents an increase in MAF. Data is only provided for patients that had both a baseline measurement and an end of treatment measurement.

    Time frame: Baseline and End of treatment

  19. KIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT

    Change in mutations in tumor tissue at baseline and end of treatment (EOT). EOT tumor biopsies were optional and there were no EOT samples collected.

    Time frame: Baseline and end of treatment

07

Results

Posted Jun 22, 2021

Participant flow

Part 1 - Dose Determining Period
Participant flow — Part 1 - Dose Determining Period
MilestoneExperimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDExperimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD
Started666666730
Patients from part 1 included in the part 2 analyses000006700
Completed666666620
Not completed000000110
Withdrew: Did not complete >21 days of treatment000000100
Withdrew: Not evaluable000000010
Part 2 - Treatment
Participant flow — Part 2 - Treatment
MilestoneExperimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDExperimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD
Started00000000217
Completed000000000
Not completed00000000217
Withdrew: Disease progression00000000118
Withdrew: Adverse event0000000049
Withdrew: Physician decision0000000012
Withdrew: Administrative000000003
Withdrew: Sponsor decision0000000028
Withdrew: Death000000001
Withdrew: Withdrawal by subject000000006
Part 1 and Part 2 End of Study
Participant flow — Part 1 and Part 2 End of Study
MilestoneExperimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDExperimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD
Started66666003217
Completed000000000
Not completed66666003217
Withdrew: Disease progression200000016
Withdrew: Adverse event101000002
Withdrew: Death04243001111
Withdrew: Lost to follow-up111000006
Withdrew: Withdrawal by subject0000000015
Withdrew: Physician decision001010008
Withdrew: Initiation of another therapy000000001
Withdrew: Sponsor decision2112200168

Outcome measures

PrimaryPart 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib

Patients with event(s) of dose-limiting toxicity

Time frame:
Cycle 1 (28 days) of treatment
Reported as:
Number · patients with event(s) of dose-limiting
Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib
patients with event(s) of dose-limitingExperimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 300 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 400 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD
Part 1: Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Avapritinib00000002
PrimaryParts 1 and 2: Number of Patients With Adverse Events (AE) and Serious Adverse Events (SAE)

The overall safety profile of the drug was assessed by reviewing the number of patients with AEs, SAEs and other events. There was no formal statistical analysis. Safety assessments continued for the duration of treatment.

Time frame:
AEs were collected from the start of study drug until 30 days after the last dose, SAEs were collected from the date of the informed consent signature until 30 days after the last dose of study drug, up to 5 years
Reported as:
Number · participants
Parts 1 and 2: Number of Patients With Adverse Events (AE) and Serious Adverse Events (SAE)
participantsExperimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDExperimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD
Participants with an Adverse Event666663216
Participants with a Serious Adverse Event345553140
PrimaryPart 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1

To evaluate objective response rate (ORR) determined by central radiology assessment per mRECIST, version 1.1 in patients with advanced GIST treated with avapritinib. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR

Time frame:
Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Reported as:
Count of participants · Participants
Part 2: Objective Response Rate (ORR) Determined by Central Radiology Assessment Per mRECIST, Version 1.1
ParticipantsPatients With a PDGFRA D842V Mutation2L Patients Without a PDGFRA D842V Mutation3L Patients Without a PDGFRA D842V Mutation
Responder361020
Non-Responder240108
SecondaryMaximum Plasma Drug Concentration (Cmax)

Maximum plasma drug concentration (Cmax) following a single dose of avapritinib

Time frame:
Cycle 1 Day 1
Reported as:
Median · ng/mL
Maximum Plasma Drug Concentration (Cmax)
ng/mLPart 1 Avapritinib (Formerly BLU-285) 300 mg QDPart 1 Avapritinib (Formerly BLU-285) 400 mg QD
Maximum Plasma Drug Concentration (Cmax)305 ± 153343 ± 181
SecondaryTime to Maximum Plasma Drug Concentration (Tmax)

Cycle 1 Day 1 PK time to maximum plasma drug concentration (Tmax)

Time frame:
Cycle 1 Day 1
Reported as:
Median · hours
Time to Maximum Plasma Drug Concentration (Tmax)
hoursPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Time to Maximum Plasma Drug Concentration (Tmax)4.0 (0.98 to 23.5)4.02 (1.97 to 24.0)
SecondaryPlasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)

Plasma drug concentration at 24 hours postdose prior to the next daily dose (C24) following a single dose of avapritinib

Time frame:
Cycle 1 Day 1
Reported as:
Mean · ng/mL
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)
ng/mLPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose (C24)134 ± 49.4185 ± 80.2
SecondaryArea Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC 0-24)

Area under the plasma concentration-time curve from time 0 to 24 hours (AUC 0-24) following a single dose of avapritinib

Time frame:
Cycle 1 Day 1
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC 0-24)
h*ng/mLPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Area Under the Plasma Concentration-time Curve From Time 0 to 24 Hours (AUC 0-24)4510 ± 17605310 ± 2080
SecondaryApparent Oral Clearance Unadjusted for Bioavailability (CL/F)

Apparent oral clearance unadjusted for bioavailability (CL/F) following a single dose of avapritinib

Time frame:
Cycle 1 Day 1
Reported as:
Mean · L/h
Apparent Oral Clearance Unadjusted for Bioavailability (CL/F)
L/hPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Apparent Oral Clearance Unadjusted for Bioavailability (CL/F)31.5 ± 15.229.9 ± 20.1
SecondaryApparent Volume of Distribution, Unadjusted for Bioavailability (Vz/F)

Apparent volume of distribution, unadjusted for bioavailability (Vz/F) following a single dose of avapritinib

Time frame:
Cycle 1 Day 1
Reported as:
Mean · L
Apparent Volume of Distribution, Unadjusted for Bioavailability (Vz/F)
LPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Apparent Volume of Distribution, Unadjusted for Bioavailability (Vz/F)1310 ± 6761340 ± 597
SecondaryTerminal Elimination Half-life (t1/2)

Terminal elimination half-life (t1/2) following a single dose of avapritinib

Time frame:
Cycle 1 Day 1
Reported as:
Mean · h
Terminal Elimination Half-life (t1/2)
hPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Terminal Elimination Half-life (t1/2)32.1 ± 15.643.5 ± 28.4
SecondaryMaximum Plasma Drug Concentration (Cmax) at Steady State

Maximum plasma drug concentration (Cmax) at steady state following 15 days of QD dosing

Time frame:
Cycle 1 Day 15
Reported as:
Mean · ng/mL
Maximum Plasma Drug Concentration (Cmax) at Steady State
ng/mLPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Maximum Plasma Drug Concentration (Cmax) at Steady State905 ± 4021140 ± 469
SecondaryTime of Maximal Concentration (Tmax) at Steady State

Time of maximal concentration (Tmax) at steady state following 15 days of QD dosing

Time frame:
Cycle 1 Day 15
Reported as:
Median · h
Time of Maximal Concentration (Tmax) at Steady State
hPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Time of Maximal Concentration (Tmax) at Steady State4.0 (0.0 to 8.17)3.99 (0.5 to 8.0)
SecondaryPlasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at Steady State (C24,ss)

Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at steady state (C24,ss) following 15 days of QD dosing

Time frame:
Cycle 1 Day 15
Reported as:
Mean · ng/mL
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at Steady State (C24,ss)
ng/mLPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Plasma Drug Concentration at 24 Hours Postdose Prior to the Next Daily Dose at Steady State (C24,ss)593 ± 263760 ± 343
SecondaryArea Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady Sate (AUC0-τ,ss) (τ=24 h)

Area under the plasma concentration-time curve over the dosing interval at steady sate (AUC0-τ,ss) (τ=24 h) following 15 days of QD dosing

Time frame:
Cycle 1 Day 15
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady Sate (AUC0-τ,ss) (τ=24 h)
h*ng/mLPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Area Under the Plasma Concentration-time Curve Over the Dosing Interval at Steady Sate (AUC0-τ,ss) (τ=24 h)16900 ± 723021300 ± 9250
SecondaryProgression-free Survival Per mRECIST Version 1.1

Progression-free survival is defined as the time in months from the start of treatment to the date of first documented progression or death due to any cause. Progression-free survival determined by central radiological assessment per modified Response Evaluation Criteria in Solid Tumors (mRECIST), version 1.1 in patients with advanced GIST. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.

Time frame:
Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Reported as:
Median · months
Progression-free Survival Per mRECIST Version 1.1
monthsPatients With a PDGFRA D842V Mutation2L Patients Without a PDGFRA D842V Mutation3L Patients Without a PDGFRA D842V Mutation
Progression-free Survival Per mRECIST Version 1.127.6 (19.5 to NA)5.5 (2.0 to 9.4)3.7 (3.6 to 5.6)
SecondaryApparent Oral Clearance at Steady State, Unadjusted for Bioavailability (CLss/F)

Apparent oral clearance at steady state, unadjusted for bioavailability (CLss/F) following 15 days of QD dosing

Time frame:
Cycle 1 Day 15
Reported as:
Mean · L/h
Apparent Oral Clearance at Steady State, Unadjusted for Bioavailability (CLss/F)
L/hPart 1 and Part 2: Avapritinib (Formerly BLU-285) 300 mg QDPart 1 and Part 2: Avapritinib (Formerly BLU-285) 400 mg QD
Apparent Oral Clearance at Steady State, Unadjusted for Bioavailability (CLss/F)21.8 ± 12.022.8 ± 11.7
SecondaryClinical Benefit Rate Determined by Central Radiology Assessment Per mRECIST, Version 1.1

Percent of patients with a complete response, partial response or stable disease lasting more than 16 weeks. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Stable disease is defined as a tumor that does not meet the criteria for progression or for response. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.

Time frame:
Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Reported as:
Count of participants · Participants
Clinical Benefit Rate Determined by Central Radiology Assessment Per mRECIST, Version 1.1
ParticipantsPatients With a PDGFRA D842V Mutation2L Patients Without a PDGFRA D842V Mutation3L Patients Without a PDGFRA D842V Mutation
Clinical Benefit372651
No Clinical Benefit12477
SecondaryResponse Rate Determined by Central Radiology Assessment Per Choi Criteria

A complete response is defined as complete disappearance of all target lesions. A partial response is ≥10% decrease tumor size at computed tomography (CT) or ≥15% decrease in tumor attenuation at computed tomography (CT) and no new lesions. The response rate is defined as complete response plus partial response.

Time frame:
Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Reported as:
Count of participants · Participants
Response Rate Determined by Central Radiology Assessment Per Choi Criteria
ParticipantsPatients With a PDGFRA D842V Mutation2L Patients Without a PDGFRA D842V Mutation3L Patients Without a PDGFRA D842V Mutation
Responder371845
Non-responder13283
SecondaryDuration of Response Determined by Central Radiology Assessment Per mRECIST, Version 1.1

Duration from time to first documented CR/PR to date of first documented disease progression or death. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Overall Response (OR) = CR + PR

Time frame:
Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.
Reported as:
Median · months
Duration of Response Determined by Central Radiology Assessment Per mRECIST, Version 1.1
monthsPatients With PDGFRA D842V Mutation2L Patients Without a PDGFRA D842V Mutation3L Patients Without a PDGFRA D842V Mutation
Duration of Response Determined by Central Radiology Assessment Per mRECIST, Version 1.122.1 (14.3 to NA)19.2 (9.2 to 19.2)10.2 (7.2 to 15.0)
SecondaryMedian PFS on Last Prior Anti-cancer Therapy

Progression Free Survival (PFS) is defined as the time in months from the start of treatment to the date of first documented disease progression or death due to any cause, which ever occurs first. PFS on last prior anti-cancer therapy is defined as the time in months from the start of last prior anti-cancer therapy to progression on that therapy.

Time frame:
Historical data collected at enrollment, all available data on prior therapy was collected
Reported as:
Median · months
Median PFS on Last Prior Anti-cancer Therapy
monthsPatients With a PDGFRA D842V Mutation2L Patients Without a PDGFRA D842V Mutation3L Patients Without a PDGFRA D842V Mutation
Median PFS on Last Prior Anti-cancer Therapy5.9 (4.2 to 8.3)31.0 (26.4 to 48.0)6.4 (4.3 to 8.3)
SecondaryChange From Baseline in Levels of KIT and PDGFRα Mutant Allele Fractions in Peripheral Blood

Change of mutant allele fraction (MAF) summarizes the largest fold change. Change from baseline only displayed for patients with pre and post treatment MAF measurements. A positive number represents an increase in MAF. Data is only provided for patients that had both a baseline measurement and an end of treatment measurement.

Time frame:
Baseline and End of treatment
Reported as:
Mean · fraction of total
Change From Baseline in Levels of KIT and PDGFRα Mutant Allele Fractions in Peripheral Blood
fraction of totalExperimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QD
Change in PDGFRA MAF8.702 ± NA
Change in KIT MAF14.398 ± NA
SecondaryKIT, PDGFRA, and Other Cancer-relevant Mutations Present in Tumor Tissue at Baseline and EOT

Change in mutations in tumor tissue at baseline and end of treatment (EOT). EOT tumor biopsies were optional and there were no EOT samples collected.

Time frame:
Baseline and end of treatment

No measurements were reported for this outcome.

Adverse events

Collected over For each patient adverse event data were collected starting at the time of the first dose of study drug until 30 days after the final dose of study drug. Serious adverse event data were collected from the time the informed consent was signed until 30 days after the final dose of study drug. On average 8 months, up to 5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QD0/6 (0%)3/6 (50%)6/6 (100%)
Experimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QD4/6 (66.7%)4/6 (66.7%)6/6 (100%)
Experimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QD2/6 (33.3%)5/6 (83.3%)5/6 (83.3%)
Experimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QD4/6 (66.7%)5/6 (83.3%)6/6 (100%)
Experimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QD3/6 (50%)5/6 (83.3%)6/6 (100%)
Experimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QD1/3 (33.3%)3/3 (100%)3/3 (100%)
Experimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD111/217 (51.2%)140/217 (64.5%)214/217 (98.6%)
Most frequent serious events
Showing 10 of 163
Most frequent serious events
EventExperimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDExperimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD
AnemiaBlood and lymphatic system disorders0/60/60/61/61/61/324/217
Face oedemaGeneral disorders0/60/60/60/60/61/30/217
HypoxiaRespiratory, thoracic and mediastinal disorders0/60/60/60/61/61/30/217
Mood alteredPsychiatric disorders0/60/60/60/60/61/30/217
Dermatitis acneiformSkin and subcutaneous tissue disorders0/60/60/60/60/61/30/217
HypertensionVascular disorders0/60/60/60/60/61/30/217
Abdominal painGastrointestinal disorders0/61/60/61/60/60/38/217
Upper gastrointestinal haemorrhageGastrointestinal disorders1/61/60/61/61/60/34/217
Gastrointestinal haemorrhageGastrointestinal disorders1/60/60/61/61/60/33/217
VomitingGastrointestinal disorders0/60/60/60/61/60/34/217
Most frequent other events
Showing 10 of 48
Most frequent other events
EventExperimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDExperimental: Part 1 and Part 2 Avapritinib (Formerly BLU-285) 300 or 400 mg QD
Decreased appetiteMetabolism and nutrition disorders1/63/62/63/62/63/388/217
Periorbital oedemaEye disorders4/64/61/64/62/61/395/217
Lacrimation increasedEye disorders2/62/62/64/62/61/376/217
DyspepsiaGastrointestinal disorders2/62/60/64/60/61/336/217
Blood bilirubin increasedInvestigations1/61/61/61/60/62/348/217
Weight decreasedInvestigations1/62/60/63/61/62/338/217
DizzinessNervous system disorders2/61/60/62/62/62/351/217
DysgeusiaNervous system disorders0/61/60/63/61/62/340/217
CoughRespiratory, thoracic and mediastinal disorders2/61/64/60/64/62/327/217
Hair colour changesSkin and subcutaneous tissue disorders2/62/61/64/62/61/350/217

Baseline characteristics

Age, Continuous
Age, Continuous(years)Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDPart 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QDTotal
Mean58.7 ± 12.2160.2 ± 6.7760.2 ± 11.8461.5 ± 10.0561.7 ± 8.3148.3 ± 20.8259.4 ± 11.0059.4 ± 10.97
Sex: Female, Male
Sex: Female, Male(Participants)Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDPart 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QDTotal
Female4310318496
Male235632133154
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDPart 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QDTotal
American Indian or Alaska Native00000022
Asian0000002222
Native Hawaiian or Other Pacific Islander00000011
Black or African American1001001012
White564543154181
More than one race00000000
Unknown or Not Reported0020202832
Region of Enrollment
Region of Enrollment(participants)Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDPart 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QDTotal
Belgium0011101316
France0011202024
Germany1201001418
Netherlands0010001112
Poland00000088
South Korea0000001717
Spain0000001111
United Kingdom1030012328
United States440332100116
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m2)Experimental: Part 1 Avapritinib (Formerly BLU-285) 30 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 60 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 90 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 135 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 200 mg QDExperimental: Part 1 Avapritinib (Formerly BLU-285) 600 mg QDPart 1 and Part 2 Avapritinib (Formerly BLU-285) 300 mg or 400 mg QDTotal
Mean24.78 ± 4.2231.61 ± 8.6328.33 ± 3.7623.78 ± 2.7124.63 ± 5.1627.15 ± 4.5425.98 ± 6.2226.09 ± 6.15
08

Study locations

19 sites
  • Scottsdale Healthcare Hospitals DBA HonorHealth
    Scottsdale, Arizona 85258, United States
  • Sarcoma Oncology Center
    Santa Monica, California 90403, United States
  • Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Cancer Treatment Centers of America
    Atlanta, Georgia 30256, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
  • Oregon Health and Science University
    Portland, Oregon 97239, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Leuven Cancer Institute University Hospitals Leuven
    Leuven, 3000, Belgium
  • Centre Leon Berard
    Lyon, 69008, France
  • Institut Gustave Roussy
    Paris, 94805, France
  • University of Duisburg-Essen
    Essen, 45122, Germany
  • Fondazione IRCCS - Istituto Nazinale dei Tumori
    Milan, 20133, Italy
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Erasmus MC Cancer Institute
    Rotterdam, 3015, Netherlands
  • Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie w Warszawie
    Warsaw, 02-781, Poland
  • Vall d' Hebron Institute of Oncology (VHIO)
    Barcelona, 08305, Spain
  • Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
09

References and documents

Publications

  • Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, Patel S, Zhou Y, von Mehren M, Hohenberger P, Villalobos V, Brahmi M, Tap WD, Trent J, Pantaleo MA, Schoffski P, He K, Hew P, Newberry K, Roche M, Heinrich MC, Bauer S. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 Oct 1;39(28):3128-3139. doi: 10.1200/JCO.21.00217. Epub 2021 Aug 3. PubMed 34343033 ↗
  • von Mehren M, Heinrich MC, Shi H, Iannazzo S, Mankoski R, Dimitrijevic S, Hoehn G, Chiroli S, George S. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. BMC Cancer. 2021 Mar 19;21(1):291. doi: 10.1186/s12885-021-08013-1. PubMed 33740926 ↗
  • Jones RL, Serrano C, von Mehren M, George S, Heinrich MC, Kang YK, Schoffski P, Cassier PA, Mir O, Chawla SP, Eskens FALM, Rutkowski P, Tap WD, Zhou T, Roche M, Bauer S. Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021 Mar;145:132-142. doi: 10.1016/j.ejca.2020.12.008. Epub 2021 Jan 16. PubMed 33465704 ↗
  • Joseph CP, Abaricia SN, Angelis MA, Polson K, Jones RL, Kang YK, Riedel RF, Schoffski P, Serrano C, Trent J, Tetzlaff ED, Si TD, Zhou T, Doyle A, Bauer S, Roche M, Havnaer T. Optimal Avapritinib Treatment Strategies for Patients with Metastatic or Unresectable Gastrointestinal Stromal Tumors. Oncologist. 2021 Apr;26(4):e622-e631. doi: 10.1002/onco.13632. Epub 2021 Jan 5. PubMed 33301227 ↗
  • Heinrich MC, Jones RL, von Mehren M, Schoffski P, Serrano C, Kang YK, Cassier PA, Mir O, Eskens F, Tap WD, Rutkowski P, Chawla SP, Trent J, Tugnait M, Evans EK, Lauz T, Zhou T, Roche M, Wolf BB, Bauer S, George S. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020 Jul;21(7):935-946. doi: 10.1016/S1470-2045(20)30269-2. Erratum In: Lancet Oncol. 2020 Sep;21(9):e418. doi: 10.1016/S1470-2045(20)30489-7. PubMed 32615108 ↗
  • Gebreyohannes YK, Wozniak A, Zhai ME, Wellens J, Cornillie J, Vanleeuw U, Evans E, Gardino AK, Lengauer C, Debiec-Rychter M, Sciot R, Schoffski P. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. Clin Cancer Res. 2019 Jan 15;25(2):609-618. doi: 10.1158/1078-0432.CCR-18-1858. Epub 2018 Oct 1. PubMed 30274985 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Mar 2020, 55 months.

Results were first posted in Jun 2021, 1 year 3 months after primary completion.

Of 21 phase 1 interventional studies under Gastrointestinal Stromal Tumors, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 77. This study's 55 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2015
First posted
Jul 27, 2015
StartActual
Aug 2015
Primary completionActual
Mar 6, 2020
CompletionActual
Jun 3, 2021
Results first posted
Jun 22, 2021
Last update
Jun 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02508532
Responsible party
Sponsor
First posted
Jul 27, 2015
Start date
Aug 2015
Primary completion
Mar 6, 2020
Completion
Jun 3, 2021
Results posted
Jun 22, 2021
Last update
Jun 21, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avapritinib

Start the discussion